Scientists test re-engineered immune cells to fight untreatable MS
NCT ID NCT06451159
Summary
This is an early-phase study testing a new personalized cell therapy called KYV-101 in 10 people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. Researchers will collect a patient's own immune cells, modify them in a lab to target B cells thought to drive MS, and infuse them back. The main goals are to check if the modified cells reach the brain and spinal cord and to find the safest dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco, Multiple Sclerosis Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.